文献速递肺结节与肺癌

晚期非小细胞肺癌的靶向治疗:新生物标志物与治疗策略

Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.
PubMed 文献 · Lancet Respir Med · 2026-09-06

该综述总结了晚期非小细胞肺癌(NSCLC)中已确立的靶点(如EGFR、ALK、ROS1、KRAS、BRAF、RET、HER2、MET、NTRK)及新兴靶点(如NRG1融合、MTAP缺失、SMARCA4缺陷)的靶向治疗进展。新型酪氨酸激酶抑制剂、双特异性抗体和抗体偶联药物改善了缓解持久性、颅内疾病控制及部分场景的总生存,但获得性耐药等因素仍限制持久获益,需重复活检和循环肿瘤DNA分析指导后续治疗。个体化治疗选择日趋复杂,涉及 CNS 疾病和寡进展管理及长期耐受性。

要点

  • 生物标志物匹配治疗改善多个分子亚组结局,需全面分子检测。
  • 新型TKI、双抗和ADC改善缓解持久性、颅内控制和部分OS。
  • 获得性耐药和异质性限制持久获益,建议重复活检和ctDNA分析。

核心结论

  • 靶向治疗已改变晚期NSCLC管理,但持久获益受获得性耐药、肿瘤异质性、谱系可塑性和脱靶逃逸限制。
  • 个体化治疗选择因单药和联合方案增多而日益复杂,需考虑CNS疾病和寡进展管理及长期耐受性。

研究设计与样本

  • 本文为Lancet Respir Med关于肺癌治疗系列的第二篇综述,总结已确立和新兴靶点的靶向治疗进展。

主要发现

  • 生物标志物匹配治疗在越来越多的分子定义亚组中改善结局。
  • 新型酪氨酸激酶抑制剂、双特异性抗体和抗体偶联药物改善了缓解持久性、颅内疾病控制,并在某些场景改善总生存。
  • 已确立靶点包括EGFR、ALK、ROS1、KRAS、BRAF、RET、HER2、MET和NTRK;新兴靶点包括NRG1融合、MTAP缺失和SMARCA4缺陷。

临床怎么用

  • 支持重复组织活检和循环肿瘤DNA分析以指导后续治疗。
  • 个体化治疗选择需综合考虑单药或联合方案、CNS疾病和寡进展管理及长期耐受性。
  • 进一步进展依赖于更有效和适应性的治疗策略以及全面分子检测、及时生物标志物检测和下一代靶向治疗的公平可及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision oncology has changed the management of advanced non-small-cell lung cancer (NSCLC). Biomarker-matched therapies now improve outcomes in an increasing number of molecularly defined subgroups. In this second paper in a Series on therapeutics in lung cancer, we summarise recent advances in NSCLC with established alterations, including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK, and discuss emerging targets, such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency. Newer generations of tyrosine kinase inhibitors, the introduction of bispecific antibodies, and antibody-drug conjugates have improved response durability, intracranial disease control, and in some settings, overall survival. However, durable benefit can remain limited by acquired resistance, tumour heterogeneity, lineage plasticity, and off-target escape, supporting repeat tissue biopsy and circulating-tumour DNA profiling to guide subsequent treatment. With several options available such as monotherapy and combination approaches, individualised treatment selection is becoming increasingly complex. We discuss these choices, including the management of CNS disease and oligoprogression, and long-term tolerability. As drug development extends beyond canonical drivers to rarer alterations and adverse co-mutations, the range of targetable disease is increasing. Further progress will depend on more effective and adaptive treatment strategies together with equitable access to comprehensive molecular profiling, timely biomarker testing, and next-generation targeted therapies.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Hendriks LEL, Lin JJ, Tan DSW, et al. Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies. Lancet Respir Med. 2026. PMID: 42702211. doi:10.1016/S2213-2600(26)00253-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。